Urine pH and Urinary Tract Infection

Centre Hospitalier Universitaire Vaudois50 enrolled

Overview

Urinary tract infections (UTI) affect the urine pH and may lead to salt precipitation such as struvite. Bacteria with urease activity are known to alkalinise urine, but not much is known on how pH is changing over time during UTI. This study aims at following urine pH progression at the time of diagnosis of UTI and during the treatment phase. Description of the change in urine pH over time will help understanding the risk of struvite formation and potential timing of intervention.

Adults presenting with UTI symptoms will be screened for infection and instructed to monitor urine pH during the course of treatment and 1 week after. Urine pH will be measured by the patients using calibrated pH-stix. Type of bacteria, antibiotics, and the type of diet will be monitored during the study.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Urinary Tract Infections Urinary Stone

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Group 1. Cystitis Inclusion Criteria: * Symptoms of dysuria, pollakiuria, no fever AND * urine-stix positive for leucocytes OR positive culture (\>10E5 cfu/ml) Group 2. Pyelonephritis Inclusion Criteria: * Unilateral flank pain, pollakiuria, dysuria, fever (\>38.5°C) AND * urine-stix positive for leucocytes OR positive culture (\>10E5 cfu/ml) Exclusion Criteria (both groups): * known urinary tract anatomic abnormalities * Presence of a urine catheter * Sepsis - septic shock * Patient taking drug interfering with urine pH (diuretics, citrate, acetazolamide, topiramate,...) * Patients with UTI diagnosed in the preceding month * Patients having received antibiotics during the preceding month * Male patient with a diagnosis of prostatitis * Presence of infected kidney cyst * Patient with diabetes * Pregnant female * Patient with obstructive pyelonephritis

Locations (1)

UniSanté

Lausanne, Canton of Vaud, Switzerland

RECRUITING

Outcomes

Primary Outcomes

Urine pH

Urine pH is monitored by the patient every morning during the treatment phase and 7 days after the end of treatment

Time frame: 21 days

Central Contacts

Charlotte Desponds, BM

CONTACT

+41795561934 Charlotte.Desponds@unil.ch

Alexandre Gouveia, MD

CONTACT

Alexandre.Gouveia@unisante.ch

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.